Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study

Oncology Group ◽

Open Label ◽

Open Label Study ◽

Oncology Group Study ◽

Label Study ◽

Peritoneal Cancer ◽

Previously Treated

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.09.032 ◽

2006 ◽

Vol 100 (3) ◽

pp. 586-590 ◽

Cited By ~ 20

Author(s):

Allan Covens ◽

John Blessing ◽

David Bender ◽

Robert Mannel ◽

Mark Morgan

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2005.11.013 ◽

2006 ◽

Vol 100 (1) ◽

pp. 27-32 ◽

Cited By ~ 227

Author(s):

Joan L. Walker ◽

Deborah K. Armstrong ◽

Helen Q. Huang ◽

Jeffrey Fowler ◽

Kenneth Webster ◽

...

Keyword(s):

Intraperitoneal Chemotherapy ◽

Gynecologic Oncology ◽

Phase Iii ◽

Stage Iii ◽

Oncology Group ◽

Phase Iii Trial ◽

Oncology Group Study ◽

A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: A gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.10.071 ◽

2010 ◽

Vol 116 (3) ◽

pp. 332-334 ◽

Cited By ~ 18

Author(s):

Thomas F. Rocereto ◽

William E. Brady ◽

Mark S. Shahin ◽

James S. Hoffman ◽

Laurie Small ◽

...

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023

Cancer Science ◽

10.1111/cas.15185 ◽

2021 ◽

Author(s):

Tadahiro Shoji ◽

Takayuki Enomoto ◽

Masakazu Abe ◽

Aikou Okamoto ◽

Takayuki Nagasawa ◽

...

Keyword(s):

Fallopian Tube ◽

Gynecologic Oncology ◽

Standard Of Care ◽

Efficacy And Safety ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Previously Treated

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Oncology ◽

10.1016/j.yonc.2011.07.016 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Resistant

A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2009.07.023 ◽

2009 ◽

Vol 115 (2) ◽

pp. 215-220 ◽

Cited By ~ 43

Author(s):

Carol Aghajanian ◽

John A. Blessing ◽

Kathleen M. Darcy ◽

Gary Reid ◽

Koen DeGeest ◽

...

Keyword(s):

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q)

Yearbook of Medicine ◽

10.1016/s0084-3873(11)00207-0 ◽

2011 ◽

Vol 2011 ◽

pp. 154-155

Author(s):

J.T. Thigpen

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2003.09.019 ◽

2004 ◽

Vol 92 (1) ◽

pp. 93-100 ◽

Cited By ~ 17

Author(s):

K Look

Keyword(s):

Phase I ◽

Gynecologic Oncology ◽

Feasibility Trial ◽

Oncology Group ◽

Oncology Group Study ◽

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.03.042 ◽

2015 ◽

Vol 137 (3) ◽

pp. 386-391 ◽

Cited By ~ 146

Author(s):

Robert L. Coleman ◽

Michael W. Sill ◽

Katherine Bell-McGuinn ◽

Carol Aghajanian ◽

Heidi J. Gray ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Parp Inhibitor ◽

Brca2 Mutation ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽